Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing

BACKGROUND: Chimeric Antigen Receptor (CAR) T cells are now standard of care (SOC) for some patients with B cell and plasma cell malignancies and could disrupt the therapeutic landscape of solid tumors. However, access to CAR-T cells is not adequate to meet clinical needs, in part due to high cost a...

Descripción completa

Detalles Bibliográficos
Autores principales: Balke-Want, Hyatt, Keerthi, Vimal, Gkitsas, Nikolaos, Mancini, Andrew G., Kurgan, Gavin L., Fowler, Carley, Xu, Peng, Liu, Xikun, Asano, Kyle, Patel, Sunny, Fisher, Christopher J., Brown, Annie K., Tunuguntla, Ramya H., Patel, Shabnum, Sotillo, Elena, Mackall, Crystal L., Feldman, Steven A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291796/
https://www.ncbi.nlm.nih.gov/pubmed/37365642
http://dx.doi.org/10.1186/s12943-023-01799-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291796/
https://www.ncbi.nlm.nih.gov/pubmed/37365642
http://dx.doi.org/10.1186/s12943-023-01799-7

Ejemplares similares